Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells.
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis.
Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Glatiramer Acetate Guards Against Rapid Memory Decline During Relapsing-Remitting Experimental Autoimmune Encephalomyelitis.
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b.
Risks of immune system treatments.
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
Spectrum of nontraumatic myelopathies in Ethiopian patients: hospital-based retrospective study.
The Role of Endogenous IFN-β in the Regulation of Th17 Responses in Patients with Relapsing-Remitting Multiple Sclerosis.
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.

Pages